Literature DB >> 19082437

Knockdown of Dicer in MCF-7 human breast carcinoma cells results in G1 arrest and increased sensitivity to cisplatin.

Ye Bu1, Chunhua Lu, Chunjing Bian, Jinghua Wang, Jing Li, Bin Zhang, Zhenya Li, Gary Brewer, Robert Chunhua Zhao.   

Abstract

Aberrant expression of microRNAs (miRNAs) in various human cancers suggests a role for miRNAs in tumorigenesis. Dicer is an essential component of the miRNA machinery, which mediates the processing of miRNAs. However, little is known about the role of Dicer in tumor proliferation and drug resistance. In this study, we found that knockdown of Dicer by siRNA led to significant G1 arrest and increased sensitivity to the DNA damaging agent, cisplatin, in breast cancer cell line MCF-7. Moreover, we found down-regulation of miR-21, a well-recognized miRNA frequently involved in a wide variety of cancers and up-regulation of cell cycle-dependent kinase inhibitor (CKI) p21 and p27. These data demonstrate that knockdown of Dicer inhibits human breast carcinoma cell growth and suggests a promising combination of anti-Dicer strategy and traditional chemotherapy to improve cancer treatment efficiency.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19082437

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  23 in total

1.  Alterations in nuclear pore architecture allow cancer cell entry into or exit from drug-resistant dormancy.

Authors:  Yayoi Kinoshita; Tamara Kalir; Jamal Rahaman; Peter Dottino; D Stave Kohtz
Journal:  Am J Pathol       Date:  2011-11-07       Impact factor: 4.307

Review 2.  microRNAs and EMT in mammary cells and breast cancer.

Authors:  Josephine A Wright; Jennifer K Richer; Gregory J Goodall
Journal:  J Mammary Gland Biol Neoplasia       Date:  2010-05-25       Impact factor: 2.673

3.  Reduction of Dicer impairs Schwann cell differentiation and myelination.

Authors:  Jonathan D Verrier; Susan Semple-Rowland; Irina Madorsky; Joseph E Papin; Lucia Notterpek
Journal:  J Neurosci Res       Date:  2010-09       Impact factor: 4.164

Review 4.  Molecular pathways involved in microRNA-mediated regulation of multidrug resistance.

Authors:  Rongrong Liao; Yuexia Lin; Lihui Zhu
Journal:  Mol Biol Rep       Date:  2018-09-07       Impact factor: 2.316

5.  Resistance to cancer chemotherapeutic drugs is determined by pivotal microRNA regulators.

Authors:  Marta Geretto; Alessandra Pulliero; Camillo Rosano; Dinara Zhabayeva; Rakhmet Bersimbaev; Alberto Izzotti
Journal:  Am J Cancer Res       Date:  2017-06-01       Impact factor: 6.166

6.  Small RNAs derived from lncRNA RNase MRP have gene-silencing activity relevant to human cartilage-hair hypoplasia.

Authors:  Leslie E Rogler; Brian Kosmyna; David Moskowitz; Remon Bebawee; Joseph Rahimzadeh; Katrina Kutchko; Alain Laederach; Luigi D Notarangelo; Silvia Giliani; Eric Bouhassira; Paul Frenette; Jayanta Roy-Chowdhury; Charles E Rogler
Journal:  Hum Mol Genet       Date:  2013-09-05       Impact factor: 6.150

Review 7.  Eukaryotic DNA damage checkpoint activation in response to double-strand breaks.

Authors:  Karen Finn; Noel Francis Lowndes; Muriel Grenon
Journal:  Cell Mol Life Sci       Date:  2011-11-15       Impact factor: 9.261

8.  Non-coding RNAs in DNA damage response.

Authors:  Yunhua Liu; Xiongbin Lu
Journal:  Am J Cancer Res       Date:  2012-11-20       Impact factor: 6.166

9.  Telomere shortening sensitizes cancer cells to selected cytotoxic agents: in vitro and in vivo studies and putative mechanisms.

Authors:  Orit Uziel; Einat Beery; Vladimir Dronichev; Katty Samocha; Sergei Gryaznov; Lola Weiss; Shimon Slavin; Michal Kushnir; Yardena Nordenberg; Claudette Rabinowitz; Baruch Rinkevich; Tania Zehavi; Meir Lahav
Journal:  PLoS One       Date:  2010-02-09       Impact factor: 3.240

10.  Pseudogene PTENP1 functions as a competing endogenous RNA to suppress clear-cell renal cell carcinoma progression.

Authors:  Gan Yu; Weimin Yao; Kiranmai Gumireddy; Anping Li; Ji Wang; Wei Xiao; Ke Chen; Haibing Xiao; Heng Li; Kun Tang; Zhangqun Ye; Qihong Huang; Hua Xu
Journal:  Mol Cancer Ther       Date:  2014-09-23       Impact factor: 6.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.